ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia (Q37980658)

26 August 2017

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia (English)

1 reference

26 August 2017

0 references

1 reference

P Ghia

14

0 references

author name string

S Pospisilova

1

1 reference

26 August 2017

D Gonzalez

2

1 reference

26 August 2017

J Malcikova

3

1 reference

26 August 2017

M Trbusek

4

1 reference

26 August 2017

D Rossi

5

1 reference

26 August 2017

A P Kater

6

1 reference

26 August 2017

F Cymbalista

7

1 reference

26 August 2017

B Eichhorst

8

1 reference

26 August 2017

M Hallek

9

1 reference

26 August 2017

H Döhner

10

1 reference

26 August 2017

P Hillmen

11

1 reference

26 August 2017

M van Oers

12

1 reference

26 August 2017

J Gribben

13

1 reference

26 August 2017

E Montserrat

15

1 reference

26 August 2017

S Stilgenbauer

16

1 reference

26 August 2017

T Zenz

17

1 reference

26 August 2017

European Research Initiative on CLL (ERIC)

18

1 reference

26 August 2017

2 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

26

1 reference

26 August 2017

7

1 reference

26 August 2017

1458-1461

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2012.25

26 August 2017

0 references

cites work

The first 30 years of p53: growing ever more complex

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

TP53 mutation and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

From pathogenesis to treatment of chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

Structural biology of the tumor suppressor p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

Mutant p53 gain-of-function in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

The mammalian nonsense-mediated mRNA decay pathway: to decay or not to decay! Which players make the decision?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

7 January 2021

Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

7 January 2021

p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

7 January 2021

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.25

7 January 2021

Identifiers

DOI

10.1038/LEU.2012.25

1 reference

26 August 2017

1 reference